A favorable trend for raloxifene 120 mg compared to placebo was also reported, respectively [22·2%, N = 4 vs. 0·0%, N = 0, OR = 5·41 (95% C.I.: 0·86–NE), RD = 0·22 (95% C.I.: −0·03–0·45)] ( Figure 2 ).
← all excerpts
A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19.
1
—
—